Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Cellectar Biosciences, Inc. is not a good growth stock. Cellectar Biosciences, Inc. is not very popular among insiders. Cellectar Biosciences, Inc. is a mediocre stock to choose.
Log in to see more information.
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for th...
CLRB Fundamental Data by TradingView

News

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia

Globe Newswire Jorge Castillo, M.D. to Present Iopofosine I 131 Activity in Bing-Neel Syndrome Andrei Shustov, M.D. to Review CLOVER WaM Pivotal Study FLORHAM PARK, N.J., Aug. 26, 2024 (GLOBE NEWSWIRE...\n more…

Cellectar Biosciences receives noncompliance notification, to restate financials
Cellectar Biosciences receives noncompliance notification, to restate financials

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Cellectar to Restate Previously Issued Financial Statements Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq
Cellectar to Restate Previously Issued Financial Statements Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Globe Newswire FLORHAM PARK, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...\n more…

Cellectar Biosciences sees cash balance sufficient into 2Q25
Cellectar Biosciences sees cash balance sufficient into 2Q25

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update
Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

Globe Newswire Management to host a conference call today at 8:30 am ETFLORHAM PARK, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical...\n more…

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024
UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

Globe Newswire FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...\n more…